This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Narrowing post #60, because the general version has more than one answer.
The honest answer on orforglipron phase 2 is that it depends, and the useful part is the list of what it depends on. Four items, in rough order of how much they matter.
Most people get the first two right and then argue about the fourth.
Orforglipron phase 2 came up in a thread eighteen months ago and was answered well. I cannot find it, which is itself the problem, so here is the reconstruction.
Recording who prepared each section makes the summary attributable, which matters when somebody reads it eighteen months later and wants to ask a question.
TRIUMPH (ongoing): Retatrutide phase 3. No results yet. Nothing should be attributed to it because it has not finished. When it does, this discussion will return to it.
On orforglipron phase 2 I would separate what is worth knowing from what is worth acting on. The first list is long and the second is short, and conflating them is how threads get heated.
Seconded. It reads as careful rather than confident, which is the right register.
Post #68 describes the usual case. This is about the unusual one.
Since orforglipron phase 2 keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone with more direct experience will review it.
Sessions on negative or null results are consistently the most instructive and the hardest to get anyone to attend.
I am confident about the direction and much less about the magnitude.
Adding the measurement that post #71 says would settle it.
Where I have landed on orforglipron phase 2, having got it wrong once in public: the direction is clear, the magnitude is not, and anyone quoting a precise magnitude has borrowed it from somewhere that did not measure it.
Where I part company with post #71, and it is a narrow parting.
Bringing the previous paper on the same question makes the session much better and doubles the preparation. Worth doing every third session rather than every one.
The strength of my opinion here exceeds the strength of my evidence.
Post #75 put the caveat in the right place and I want to underline it.
The question underneath orforglipron phase 2 is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it.
Write down what you would expect to see under each hypothesis before you collect anything. If they predict the same observation, collecting it will not help.
That is clearer than the version I had in my head. Thank you.
Critical appraisal template: (1) What did the trial set out to estimate? (2) Could the design answer that question? (3) Was the population sufficiently similar to your population to apply the results? (4) What was the absolute effect, not just the relative one? (5) What are the two strongest criticisms available?
If you are new and reading this thread for the answer to orforglipron phase 2: the answer is conditional, the conditions are in the third reply, and the rest of the thread is worth skipping.
Worth stating the null on orforglipron phase 2 before we explain it: the observation may be nothing. That possibility deserves a sentence and usually does not get one.
Where I part company with post #86, and it is a narrow parting.
The most common failure mode is spending fifty minutes on the effect size and ten on the population. Reversing that ratio would improve most sessions.
I would be interested in a counterexample if anyone has one.
Taking post #88 at face value and following it one step further.
I read the earlier replies on orforglipron phase 2 twice before writing this, because I had assumed the opposite and wanted to be sure I was disagreeing with what was said rather than what I expected.
Post #86 and I disagree about the size of the effect, not about the direction.
The arithmetic on orforglipron phase 2 is the easy part and it is where the errors are, which is an uncomfortable combination. Show your working and someone will catch it.